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Available online 9 February 2016In the last decade,mumps virus (MuV) causes outbreaks in highly vaccinated populations. Sub-optimal T cell im-
munity may play a role in the susceptibility tomumps in vaccinated individuals. T cell responses to mumps virus
have been demonstrated, yet the quality of the MuV-speciﬁc T cell response has not been analyzed using single
cell immunological techniques. Herewe developed an IFNγ ELISPOT assay to assessMuV-speciﬁc T cell responses
in peripheral blood mononuclear cells (PBMC) of healthy (vaccinated) donors and mumps patients. Various
in vitro MuV-speciﬁc stimulation methods of PBMC were compared, using either live or inactivated MuV alone
or MuV-infected autologous antigen presenting cells, i.e. Epstein Barr Virus-transformed B lymphoblastoid cell
lines (EBV-BLCL) or (mitogen pre-activated) PBMC, for their ability to recall IFNγ-producing responder cellsmea-
sured by ELISPOT. For the detection of MuV-speciﬁc T cell responses, direct exposure (24 h) to live MuVwas the
preferred stimulation method when assay sensitivity and practical reasons were considered. Notably,
ﬂowcytometric conﬁrmation of data revealed that primarily T cells and NK cells produce IFNγ upon live MuV
stimulation. Depleting PBMC from CD56+ NK cells prior to stimulation with live MuV led to the enumeration
of MuV-speciﬁc T cell responses by ELISPOT. Our assay constitutes a tool to evaluate memory MuV-speciﬁc T
cell responses in MuV vaccinated or infected persons. Furthermore, this study provides evidence that live MuV
not only induces IFNγ production by T cells, but also by NK cells.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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IFNγ1. Introduction
Despite high coverage of measles–mumps–rubella (MMR) vaccina-
tion in national immunization programs, inmany countriesmumps out-
breaks among vaccinated young adults have been observed in the last
decades (Dayan et al., 2008; Kaaijk et al., 2008). Relative high exposure
to circulating mumps virus (MuV) due to social crowding (schools,
universities), mismatch between the genotype of circulating MuV and
vaccine strain, andwaning of vaccine induced immunity have been sug-
gested to causemumps outbreaks (Kaaijk et al., 2008; Fanoy et al., 2011;
Kontio et al., 2012). CD4+ T helper (Th) or CD8+ cytotoxic T cells (CTL)
are, in addition to antibodies and B cell responses, essential in the elim-
ination of virus infected target cells. Whether sub-optimal T cell immu-
nity plays a role in the susceptibility tomumps in vaccinated individuals
is unknown. Assays that can assess the quality of MuV-speciﬁc T cell
response in vaccinated populations are lacking. The pro-inﬂammatory
cytokine IFNγ is a good indicator of antigen-speciﬁc cellular immunity
and MuV-speciﬁc IFNγ secretion has been shown (Jokinen et al., 2007;
Hanna-Wakim et al., 2008; Vandermeulen et al., 2009). ELISPOT is alaan 9, 3721 MA Bilthoven, The
. This is an open access article undersensitive method to enumerate IFNγ-producing antigen-speciﬁc mem-
ory cells after short in vitro restimulation of PBMC (Schmittel et al.,
1997), and can be a useful tool for the analysis of the human T cell re-
sponse against MuV. However such method has not been developed
yet in the context of mumps virus.
Activation of virus-speciﬁc T cells depends on presentation of the
cognate antigen as protein fragments by antigen presenting cells
(APC) in the context of molecules of theMajor Histocompatibility Com-
plex (MHC) class I or II. Short in vitro coculture with MuV-infected
autologous cells could be a manner to activate memory virus-speciﬁc
T cells present in PBMC. Depending on the type of stimulator cell used,
the antigen will be presented more or less efﬁciently by MHC class I
and/or II molecules. Autologous Epstein Barr Virus (EBV) transformed
B lymphoblastoid cell lines (BLCL), provided they are susceptible to
MuV infection, can be used for MuV-speciﬁc stimulation. MuV-
infected autologous PBMC can also be used to prepare MuV-speciﬁc
stimulator cells, yet pre-activation of the PBMC may be necessary
since in general replicating cells are more susceptible to virus infection
(Miller et al., 1990). Another in vitro stimulation approach is adding live
MuV directly to responder PBMC, thereby infecting susceptible cells
during the culture period, resulting in antigen processing and presenta-
tion via MHC I or II routes that could stimulate responder cells in
the PBMC. Alternatively, responder PBMC can be stimulated withthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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antigen-presenting cells via MHC class II route. In this study, we com-
pared various ex vivo stimulation methods for the development of an
IFNγ ELISPOT that can be used to analyze the presence of functional
MuV-speciﬁc T cells in PBMC. Supporting ﬂow-based analyses were
performed to characterize the phenotype of cell types within PBMC
that are susceptible for MuV infection and to assess the contribution of
individual cell subsets to the MuV-speciﬁc IFNγ response.
2. Materials and methods
2.1. Subject population and peripheral blood sampling
Volunteers were recruited in accordance with principles expressed
in theDeclaration of Helsinki. Donor blood of healthy adultswas obtain-
ed from Sanquin Bloodbank (Project BS03.0015-X, Amsterdam) or via
the blood donor system of the National Institute for Public Health and
the Environment (RIVM) in the Netherlands. Donor blood of mumps
cases was collected as part of an observational clinical study VAC-263
performed by RIVM between November 2011 and May 2013 (Kaaijk
et al., 2015). Ethical committee approval was obtained and clinical
study was performed according to EU Good Clinical Practice guidelines
and the principles outlined in the Helsinki Declaration (clinical study
number NL37852.094.11). Laboratory-conﬁrmed symptomatic mumps
cases (N18 years) were identiﬁed through the web-based system
OSIRIS for national registration of compulsory notiﬁable diseases of
the Netherlands. For all mumps cases and a selection of healthy donors
from the internal blood donor system, information aboutMMRvaccina-
tion history was available. All volunteers in this study provided written
informed consent for the collection of samples and subsequent analysis.
2.2. Mumps virus
Vero cells were inoculated with live MuV (Jeryl-Lynn strain)
(Mumpsvax, Merck) and cultured in DMEM containing 2% FCS at
34 °C. Supernatant of MuV infected cells was harvested at peak cyto-
pathic effect (~90%), centrifuged (485 ×g), ﬁltered (5 μm) and the
resultingMuV stockwas snap-frozen and stored at−80 °C. Supernatant
of uninfected Vero cellswas used asmock control after a freeze-thawing
treatment to lyse cells analogous to virus-infected cells. Plaque forming
units (PFU) of the MuV stock (5.4 × 106 PFU/ml) was determined in a
virus titration assay. Brieﬂy, Vero cells were seeded in 96-wells plates
and cultured till conﬂuency o.n. Serial dilutions of the MuV stock was
added in DMEM containing 1% FCS and incubated for 4 h at 37 °C. Sub-
sequently, medium was removed and methylcellulose (MC) medium,
containing 1%MC, 1% FCS in DMEM, was added to prevent virus spread.
After 48 h at 37 °C, virus-infected cell foci were visualized by ﬁxing cells
with acetone/methanol (40%/60%), incubation with anti-MuV nucleo-
protein monoclonal antibody (clone 7B10, Abcam) followed with sec-
ondary horseradish peroxidase (HRP)-labeled antibody and staining
with 3,3′,5,5′-Tetramethylbenzidine (TMB) substrate. Virus-infected
cell foci were counted on the AID iSpot reader using AID ELISpot soft-
ware (AID diagnostika). A stock of inactivatedMuVwas prepared by ex-
posing the virus UVC-light irradiation (254 nm, 5 min at 1000 mJ/cm2)
(UVC 500, Hoefer).
2.3. PBMC isolation and generation of Epstein Bar Virus (EBV) Transformed
B-LCL
Peripheral blood mononuclear cells (PBMC) were isolated from
donor blood by centrifugation on a Ficoll–Hypaque gradient (Pharmacia
Biotech). PBMCwere cryopreserved (in 90% FCS/10%DMSO) at−135 °C
before thawing for use as responder cells or autologous stimulator cells.
Plasma samples were stored at−80 °C, MuV-speciﬁc IgG levels were
determined as described elsewhere (Kaaijk et al., 2015). BLCLwere gen-
erated by incubating 1 × 106 PBMC in RPMI-1640 culture medium(Gibco) in the presence of 1% fetal calf's serum (FCS) with 500 μl B95-
8 EBV supernatant for 1 h in a CO2 incubator at 37 °C. Subsequently,
cells were cultured in RPMI complete medium containing 10% FCS and
1 μg/ml of the mitogen phytohaemagglutinin (PHA) in a 48-wells ﬂat
bottom plate. Thereafter cells were cultured in RPMI complete medium
containing 10% FCS for 2–4 weeks in ﬂasks and split when necessary.
BLCL were cryopreserved at −135 °C until further use (described in
Section 2.4).
2.4. MuV infections of autologous stimulator cells
Optimal conditions to prepare MuV-infected autologous stimulator
cells were determined in pilot experiments (withMOI ranging between
0.1 and 3 and duration of MuV incubation of 1 h, 4 h or 24 h (i.e. entire
culture period of ELISPOT assay).MuV-F protein expressionwas veriﬁed
as described in Section 2.5 on the stimulator cells at the optimumof 24h
after the different time periods of live MuV exposure, in order to deter-
mine the infection efﬁciency. BLCL were infected with MuV (at optimal
MOI of 2, i.e. 1 × 106 cells in 370 μl MuV stock) or withmock control su-
pernatant for 1 h and subsequently washed twice before use as stimula-
tor cells in the ELISPOT assay. PHA-PBMC were generated by culturing
PBMC in RPMI containing 10% FCS, IL-2 (2 ng/ml) and PHA (2 μg/ml)
for 3 days. PHA-PBMC were infected with MuV (with optimal MOI of
0.1, i.e. 1 × 106 cells in 200 μl MuV stock diluted in RPMI mediumwith-
out FCS), or with mock control supernatant, for 1 h and subsequently
washed twice before use as stimulator cells. PBMC as stimulator cells
were infected with MuV (with optimal MOI of 2, i.e. 1 × 106 cells in
370 μl MuV stock), or with mock supernatant for 1 h and subsequently
washed twice before use as stimulator cells in the ELISPOT assay.
2.5. MuV-speciﬁc stimulation of responder PBMC and IFNγ ELISPOT assay
The various autologous stimulator cells, i.e. respectively BLCL, PHA-
PBMC, or PBMC (prepared as described in Section 2.4), were added to
2 × 105 responder PBMC per well in AIM-V medium (Gibco) with 2%
human AB-serum (Harlan). The stimulator cell/responder PBMC ratio
ranged from 1:5 to 1:80. In separate stimulations, live MuV (MOI
2) was directly added to responder PBMC and either after 1 h at 37 °C
subsequently washed twice before plating (Live 1 h) or plated without
washing step (Live 24 h) on the ELISPOT plates both at 2 × 105 and
1 × 105 PBMC per well in AIM-V medium (Gibco) with 2% human
AB-serum (Harlan). Besides live MuV, UVC-light (254 nm, 5 min at
1000 mJ/cm2) inactivated MuV (1 μg/ml) was directly added to re-
sponder PBMC on the ELISPOT plates both at 2 × 105 and 1 × 105
PBMC per well in AIM-V medium (Gibco) with 2% human AB-serum
(Harlan). Staphylococcal Enterotoxin B (SEB) (Sigma) stimulation, at a
concentration of 1 μg/ml, was performed on every tested sample as a
positive control.
The human IFNγ ELISPOT assay (Mabtech)was performed according
tomanufacturer's protocol. Brieﬂy, ELISPOT plates (Millipore)were pre-
wetted with 35% ethanol for ≤1 min and washed with sterile water.
Subsequently, plates were coated with anti-human IFNγ-speciﬁc cap-
ture antibody diluted in PBS at 5 μg/ml o.n. at 4 °C. Plates were treated
for 1 h with AIM-V (Gibco) medium containing 2% HS before cells
were added as described above. The various MuV-stimulated cells were
incubated at 37 °C for 24 h in the presence of 5% CO2. Plates were
exposed to UVC-light irradiation (254 nm, 5 min at 1000 mJ/cm2)
(UVC 500, Hoefer) for biosafety purpose to inactivate MuV. Plates
were washed with PBS before detection antibody, mouse anti-human
IFNγ-biotin diluted in PBS/0.5% FCS, was added at a concentration of
1 μg/ml for 2 h. After washing with PBS, plates were incubated with
Streptavidin-Alkaline-Phosphatase (SA-ALP) (Sigma) followed by de-
velopment with 5-Bromo-4-chloro-3-indolyl phosphate/nitroblue tet-
razolium (BCIP/NBT) substrate (Sigma). The spots were counted on
the AID iSpot reader using AID ELISpot software (AID diagnostika). Fre-
quencies of MuV-speciﬁc IFNγ producing cells were calculated by
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number of spots detected in the presence of MuV (average of duplo),
and were given as IFNγ spot forming cells (SFC)/1 × 105 PBMC.
2.6. Flowcytometry
To analyze the number of MuV-infected cells, expression of MuV-F
protein was determined by ﬂowcytometry. PBMC were infected with
MuV as described in 2.3 and incubated with biotin-labeled anti-MuV-F
protein mAb (Mum80) (kindly provided by Dr. G. Berbers, RIVM, The
Netherlands) (Berbers et al., 1993). Subsequently, cells were stained
with PerCP-Cy5.5-conjugated anti-CD3 (BD), APC-conjugated anti-
CD19 (BD), PE-conjugated anti-CD56 (BD), Paciﬁc Blue-conjugated
anti-CD8 (BD), PE-Cy7-conjugated anti-CD4 (Biolegend) and LIVE/
DEAD® Fixable Aqua Dead Cell Stain Kit (Invitrogen) for 30 min at
4 °C in FACS buffer (PBS (pH 7.2) supplemented with 0.5% BSA (Sigma
Aldrich) and 0.5 mM EDTA (ICN Biomedicals). Data was acquired on
FACS Canto II and analyzed using FlowJo software (Tree Star), gating
on singlets (FSC-A/FSC-H) and excluding Aqua+ (dead) cells (Supple-
mentary Fig. 1A).
For intracellular cytokine stainings (ICS), cells were ﬁxed, perme-
abilized, and stained with APC-conjugated anti-IFNγ (BD) using the
Foxp3/Transcription Factor Staining Buffer Set (eBioscience), according
to the manufacturer's protocol. Data were acquired on a FACS Canto II
(BD), gated (Supplementary Fig. 2) and analyzed using FlowJo software
(Tree Star).
2.7. Depletion of CD56+ cells in PBMC
PBMCwere depleted for CD56+ cells bymagnetic sorting using anti-
CD56 microbeads (Miltenyi Biotech) according to the manufactures
protocol. The purity of the CD56-depleted PBMC samples, veriﬁed by
ﬂowcytometry, was N99% (Supplementary Fig. 3).
2.8. Statistical analysis
Data were analyzed with Graphpad Prism version 6. Statistical sig-
niﬁcance of differences amongmock andMuV responseswas calculated
using paired t-tests. Statistical signiﬁcance of differences of column
means compared to a hypothetical value was calculated using One-
sample t-tests. P-values of ≤0.05 were considered signiﬁcant.
3. Results
3.1. Generation of MuV-infected stimulator cells
To assess whether BLCL or PBMC were susceptible to MuV infection
and could be used as APC in an ELISPOT assay, MuV infection of these
cells was evaluated by determination of MuV-F protein expression.
BLCL from ﬁve donors were infected with MuV (MOI 2) for 1 h and ex-
pression of MuV-F protein on the cell surface was observed on 1.6–
13.9% (average 6.2%) of the cells at 24 h after infection (Fig. 1A). Like-
wise, PBMC were inoculated with MuV (MOI 2) for 1 h, and 24 h later
0.2–9.5% (average 3.5%) of the cells expressed MuV-F protein on cell
surface indicatingMuV infection (Fig. 1A). To increase infection efﬁcien-
cy of mumps in PBMC, PBMCwere activated with PHA (PHA-PBMC) for
3 days prior to MuV infection. PHA-activated PBMC were more suscep-
tible to MuV infection, since optimal infection was achieved with MOI
0.1 and 3.1–13.3% (average 7.4%) of cells expressed MuV-F protein
(Fig. 1A). Using the optimized MuV infection conditions, the viability
of the cells was not affected by MuV infection compared to mock-
infected stimulator cells. Thus, BLCL, PHA-PBMC as well as PBMC ap-
peared to be susceptible to MuV infection, which is a pre-requisite to
function as APC.
TheMuV-infection rates of thedifferent cell typeswithin PBMCwere
analyzed (Fig. 1B). MuV-infected cells were mostly CD3+ T cells(average 65.03% of MuV-F+ cells), followed by signiﬁcant amounts of
CD3−CD19−CD56+NK cells (average 18.53%) and CD3−CD19−CD56−
cells (veriﬁed as mainly CD14+ monocytes in separate ﬂowcytometry
staining, Supplementary Fig. 1B) (average 14.14%), and lower numbers
of CD19+ B cells (average 2.26%) (Fig. 1C, left panel). Within MuV-
F+CD3+ T cells, mostly CD8+ and CD4+ T cells (average 39.43% and
38.10% of MuV-F+CD3+ cells, respectively) were infected by MuV
(Fig. 1C, right panel). Notably, also signiﬁcant numbers of CD3+CD4−-
CD8−CD56− cells (veriﬁed as mainly γδ TCR+ cells in separate
ﬂowcytometry staining, Supplementary Fig. 1C) (average 9.10%) and
NKT cells (CD3+CD56+; average 4.68%) were identiﬁed within the
MuV-F+CD3+ T cells (Fig. 1C, right panel). In absolute numbers, MuV
infected cells within PBMC comprise mostly CD8+ and CD4+ T cells.
Yet when taking into account the proportion of the distinct cell types
present in total PBMC, MuV seems to infect preferentially NK cells,
NKT cells and γδ T cells (Fig. 1D).
3.2. Comparing different stimulationmethods to detect cellular responses to
MuV
We tested MuV-speciﬁc IFNγ production of PBMC in response to
different MuV stimulation methods in ELISPOT assays. Cryopreserved
PBMC of MMR-vaccinated healthy adults were available to assess
MuV-speciﬁc T cell responses. All donors showed detectable MuV-
speciﬁc IgG levels in serum ranging from 212–556 RU/ml (data not
shown). MuV-infected BLCL, PHA-PBMC or PBMCwere used as stimula-
tor cells in various ratios compared to a ﬁxed amount of responder
autologous PBMC (2 × 105 cells/well) in samples of six donors. The var-
ious stimulator cells and used stimulator cell/responder PBMC ratios
showed distinct sensitivity. BLCL and PHA-PBMC stimulator cells in-
duced high background, as observed in mock control wells, compared
to PBMC stimulator cells, and background correlated with the amount
of added stimulator cells (Fig. 2A and Supplementary Fig. 4). Overall,
the stimulator cell/responder PBMC ratio with the highest sensitivity
to measure MuV-speciﬁc IFNγ-producing cells was 1:80 for BLCL, 1:5
for PHA-PBMC and 1:5 for PBMC stimulator cells (Supplementary
Fig. 4). Using the optimal stimulator cell/responder PBMC ratio, all
types of MuV-infected stimulator cells were able to evoke speciﬁc
IFNγ-production. MuV wells showed average 109 (range: 14–221),
119 (45.5–155) and 117 (36–200) IFNγ SFC/1 × 105 PBMC for BLCL,
PHA-PBMC and PBMC respectively, compared to control wells contain-
ing responder PBMC and mock-infected stimulator cells, average 57
(range: 8–107), 65 (10–91) and 27 (0–91) IFNγ SFC/1 × 105 PBMC, re-
spectively (Fig. 2B). Although with all stimulator cell methods signiﬁ-
cant MuV-speciﬁc responses were detected, the PBMC stimulator cells
performed the best, i.e. inducing high MuV-speciﬁc responses and low
background (Fig. 2B).
Instead of using separate MuV-infected stimulator cells, MuV can
also be directly added to responder PBMC. We compared MuV-speciﬁc
IFNγ production in PBMC ofMMR vaccinated donors after various direct
MuV stimulation methods in which live MuV was washed away after
1 h infection (n = 9) or in which live (n = 10) or UVC-inactivated
MuV (n = 8) was present during ELISPOT culture period (24 h). MuV-
speciﬁc IFNγ-producing cells were detected with all direct stimulation
methods, since an increase in number of IFNγ SFC was visible in wells
containing either live 1 h (including wash step), live 24 h or inactive
24 h MuV stimulated PBMC (Fig. 2C). MuV wells showed average 192
(range: 69–289), 93 (21–235) or 52 (4–133) IFNγ SFC/1 × 105 PBMC,
respectively) compared to control wells average 6 (range: 0–36), 8
(0–22) or 37 (2–137) IFNγ SFC/1 × 105 PBMC, respectively) (Fig. 2D).
However, the assay sensitivity, in terms of signal to noise ratio, was
higher for live 1 h and 24 h MuV stimulation compared to inactive
MuV stimulation (Fig. 2D). Although the live 1 h MuV stimulation
method was more sensitive compared to the live 24 h MuV stimulation
method, the amount of IFNγ SFC as determined after the live 1 h MuV
stimulation was in some samples too numerous to count in a reliable
Fig. 1.MuV infection efﬁciency in stimulator cell populations. BLCL, PHA-PBMC and PBMC stimulator cells were infected with MuV (MOI 2, MOI 0.1 and MOI 2, respectively) for 1 h. The
expression ofMuV-F protein on the cell surface, indicative for MuV infection, of stimulator cells was analyzed by ﬂowcytometry after 24 h. (A) PercentageMuV-F+ of viable cells for BLCL,
PHA-PBMC and PBMC stimulator cell populations (n= 5 donors). (B) Representative dot plots of MuV-F protein expression onmock- and MuV-infected (MOI 2 for 1 h) PBMC, 24 h after
infection. (C) Cell type distribution within MuV-F+ cells (left panel) and MuV-F+ T cells (CD3+CD19−) based on CD3, CD4, CD8, CD19 and CD56 expression. Average of 3 tested donors.
(D) MuV infection efﬁciency of different cell types within PBMC is shown as the ratio % cell type of MuV-F+ cells/% cell type of total viable cells. The results are mean ratios ± SD of MuV-
infected PBMC of 3 donors. Ratios N 1 (dotted line) indicate preferential MuV infection of the particular cell type. * p b 0.05.
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pared with the live 1 h MuV method considering less washing steps
and consequently loss of cells. The amount of IFNγ SFC after inactivated
MuV stimulationwas relatively low (average 52 IFNγ SFC/1× 105 PBMC
compared to 93 IFNγ SFC/1 × 105 PBMC after live 24 h MuV stimula-
tion), even when a two-fold of cell number was used in the assay.
However, inactivated MuV stimulation provides the opportunity to
investigate the IFNγ response when MuV antigens are presented via
the MHC class II route.
3.3. MuV-speciﬁc IFNγ production by distinct cell populations
Of the investigatedMuV stimulations, the live 24 hMuV stimulation
methodwas preferredwhen assay sensitivity and practicalitywere con-
sidered and was therefore used for further analysis. In addition, the in-
active 24 h MuV stimulation method was also selected for further
analysis, to be able to compare two methods with probably different
routes of antigen presentation. In line with the ELISPOT results, we de-
tected more IFNγ-producing cells after live MuV compared to inactive
MuV stimulation by intracellular IFNγ staining using ﬂowcytometry in
the viable cell population (Fig. 3A). MuV-speciﬁc IFNγ production
could be found in the CD3+ T cell compartment after both live MuV
and inactive MuV stimulation (Fig. 3A and B). Moreover, a relatively
large percentage of CD56-expressing NK cells produced IFNγ after live
but not after inactive MuV stimulation (Fig. 3A and B). In accordance
with this ﬁnding, when only isolated CD56+ cells, representing mainly
NK cells, were incubated with live or inactive MuV, indeed only live
MuV induced IFNγ SFC in ELISPOT (Fig. 3C). The IFNγ production bylive MuV stimulated NK cells was very variable between donors. Al-
though the frequency of NK cells in PBMC (5–10%) is much lower than
CD4+ and CD8+ T cells (60–70% and 15–20%, respectively), the data in-
dicate that live MuV stimulation may induce signiﬁcant numbers of
IFNγ producing NK cells in PBMC.
The aim of this study was to develop an assay to evaluate MuV-
speciﬁc T cell responses. Since the live MuV stimulation protocol
seemed to induce besides IFNγ-producing T cells also IFNγ-producing
CD56+ NK cells (Fig. 3), we performed the ELISPOT assay with CD56-
depleted PBMC of healthy vaccinated donors to be able to focus on T
cell responses. In line with the ﬂowcytometric data, CD56+ cells were
responsible for a signiﬁcant amount of IFNγ SFC in ELISPOT after live
MuV stimulation in healthy vaccinated donors (Fig. 4A). In PBMC that
were depleted for CD56+ cells, the amount of IFNγ SFC detected was
on average 22.0% (range 10.12–38.13%) of responses detected in non-
depleted PBMC. Yet CD56-depletion did not have a signiﬁcant effect
on the IFNγ-response in inactive MuV stimulated samples (Fig. 4A).
These data indicate that live MuV but not inactivated MuV induces sig-
niﬁcant numbers of IFNγ producing NK cells.
3.4. MuV-speciﬁc IFNγ production by T cells in mumps patients compared
to healthy vaccinated donors and the contribution of NK cells
The MuV-speciﬁc IgG level in serum of mumps patients has been
shown to reach 10–50 fold higher values than (vaccinated) healthy
donors (Kaaijk et al., 2015). The frequency of MuV-speciﬁc IFNγ-
producing T cells may therefore also be higher in mumps patients
compared to (vaccinated) healthy controls. To study the MuV-speciﬁc
Fig. 2. Comparing different stimulation methods to detect MuV-speciﬁc cellular responses. Cryopreserved PBMC of recently (1–2 months) MMR-vaccinated healthy adults were thawed
and stimulated with autologousMuV-infected stimulator cells (A, B) or were stimulated directly with live or inactiveMuV (C, D) orwere stimulatedwith their respectivemock control as
indicated. After 24 h, IFNγ-producing cellswere analyzed by ELISPOT. (A) Representative IFNγ ELISPOTwells for the various stimulator cellmethods. Stimulator cell/responder PBMC ratio
was 1:80 for BLCL, 1:5 for PHA-PBMC and 1:5 for PBMC stimulator cells. The numbers in the lower left corners indicate counted spots. (B) Frequency (mean) of IFNγ spot forming cells (SFC
per 1 × 105 responder PBMC after 24 h stimulation as indicated (n= 6 donors). (C) Representative IFNγ ELISPOT wells for the various direct stimulationmethods. Live MuVwas washed
away after 1 h infection (Live 1 h) or present during ELISPOT culture period (Live 24h). UV-inactivatedMuVwas present during the 24 h ELISPOT culture period. The numbers in the lower
left corners indicate counted spots. (D) Frequency (mean) of IFNγ SFC per 1×105 PBMC after 24 h stimulation as indicated (n=9, 10 and 8 samples for Live 1 h, Live 24h and InactiveMuV
stimulation, respectively). * p b 0.05, ** p b 0.01, *** p b 0.001.
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contribution of IFNγ produced by NK cells after live MuV stimulation,
the effect of CD56 depletion in an ELISPOT using cryopreserved PBMC
samples of mumps patients was studied (Fig. 4A). In contrast to the
live MuV-induced IFNγ responses measured in healthy vaccinated
donors, there was no signiﬁcant decrease in the amount of IFNγ-spots
detectedwhenCD56+ cells frompatientswere depleted (Fig. 4A). How-
ever, as was the case for healthy controls (Fig. 3C), CD56+ cells isolated
from PBMC of mumps patients did also produce signiﬁcant amounts of
IFNγ in response to live MuV stimulation (Fig. 4B). CD56-depletion
had no signiﬁcant effect on the inactive MuV-induced IFNγ responses
(Fig. 4A) and inactive MuV did not induce IFNγ production in isolated
CD56+ cells (Fig. 4B), as was also observed in the healthy controls
(Fig. 3C). The data suggest that depending on the magnitude of the
MuV-speciﬁc response, CD56+ cells contribute to a greater or lesser ex-
tent to the MuV-speciﬁc IFNγ-responses in PBMC samples. Altogether,
IFNγ-producing MuV-speciﬁc cellular responses can be analyzed by
IFNγ ELISPOT after live and inactiveMuV stimulation. To be able tomea-
sure MuV-speciﬁc T cell responses, ﬁrst CD56+ cells should be depleted
from the PBMC samples.
4. Discussion
In this study, we aimed to develop an IFNγ ELISPOT for the analysis
of human T cell response againstMuV. After comparing various stimula-
tionmethods,wemade several observations. First, direct liveMuV stim-
ulation is suitable for the analysis of mumps-speciﬁc T cell responses
(Fig. 2). Second, ﬂowcytometric conﬁrmation data revealed that pri-
marily T cells and NK cells produce IFNγ upon live MuV stimulation
(Fig. 3A and B). Thus when investigating MuV-speciﬁc T cell responses,
caution should be taken when interpreting the IFNγ ELISPOT results ofPBMC stimulated with live MuV since no discrimination can be made
between NK- or T cell-derived IFNγ. This may also apply for ELISPOT
and ELISA results when other live virus stimulations are used. Third,
the contribution of live MuV-induced IFNγ production by CD56+ NK
cells varied in the tested samples, and seems to depend on the immune
status of the donor (Figs. 3C and 4A). Interestingly, the contribution of
IFNγ-producing NK cells in total PBMC was evident in samples of
healthy controls but not in samples of mumps patients, while when
stimulated separately, NK cells of both healthy controls andmumps pa-
tients were capable of producing signiﬁcant amounts of IFNγ (Fig. 4).
One difference in these samples is the magnitude of the mumps-
speciﬁc response. Levels of MuV-speciﬁc IgG in tested the mumps pa-
tients ranged from 2934–23,178 RU/ml while the levels in tested
healthy controls ranged from 212–556 RU/ml. Also, the number of
IFNγ-producing T cells (in CD56-depleted cultures) was higher in
mumps patients. These data suggest that when mumps-speciﬁc im-
mune responses are high, the contribution of IFNγ-producing NK cells
is relatively small in the MuV-speciﬁc IFNγ responses measured in
total PBMC. Yet by depleting PBMC for CD56+ cells before stimulation
with live MuV, MuV-speciﬁc T cell responses can be measured by
ELISPOT in all tested samples.
We found signiﬁcant NK cell-derived IFNγ production in response to
live MuV in both healthy controls and mumps patients (Figs. 3 and 4).
NK cells are well known for their innate effector functions, including
IFNγ production, to kill virus-infected cells in the ﬁrst line of defense
(Lanier, 2008). Furthermore, T cell-dependent production of IFNγ by
NK cells in response to live and inactivated virus but also peptide stim-
ulation has been shown (He et al., 2004; Nielsen et al., 2015; Horowitz
et al., 2012; Loo et al., 2009). The IL-2 produced by antigen-speciﬁc
memory T cells was shown to be a mechanism for T cell-dependent
NK cell activation (He et al., 2004; Nielsen et al., 2015). In longitudinal
Fig. 3.MuV-speciﬁc IFNγ production by T cells and NK cells. (A, B) Cryopreserved PBMC of healthy adults were thawed and stimulated with live or inactive MuV or mock control as
indicated and the presence and phenotype of IFNγ-producing cells were analyzed by ICS using ﬂowcytometry after 24 h. (A) Representative dot plots of IFNγ-producing cells after
MuV stimulation as indicated and gated on total cells (left panels), CD3+CD56− T cells (middle panels) and CD3−CD56+ NK cells (right panels). Percentages in the right upper
corners indicate IFNγ+ cells within the gated cell population. (B) Percentage (mean ± SD) CD3+CD56− T cells and CD3−CD56+ NK cells within IFNγ+ cells after live or inactivated
MuV stimulation as indicated. Results indicate averages of 4 tested donors. (C) CD56+ cells were isolated from PBMC of healthy adults and incubated with live or inactive MuV for
analysis by IFNγ ELISPOT. Frequency of IFNγ spot forming cells (SFC) per 1 × 105 CD56+ NK cells after 24 h stimulation as indicated (n = 8 samples).
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in increased frequency of IFNγ-producing NK and T cells (Long et al.,
2008). Interestingly, inactivated split inﬂuenza vaccination induced in-
ﬂuenza virus-speciﬁc NK cells that recognize the virus via theNKp46 re-
ceptor and increased frequencies were sustained for at least 6 months
after vaccination (Dou et al., 2015), indicating that NK cells can display
immunological memory (Min-Oo et al., 2013). Thus, the NK cell derived
IFNγ-responses measured in the ELISPOT assay could have innate as
well as adaptive features. Further research should investigate whether
liveMuV induces both innate and adaptiveNK responses and the under-
lying mechanisms of the induced IFNγ production by NK cells.
Human antigen-speciﬁc T cell responses depend on direct interac-
tions between T cells with their speciﬁc T cell receptor (TCR) and APC
which display cognate antigen in the context of either MHC class I or II
molecules (for CD8+ or CD4+ T cells, respectively). Thus, depending
on the type of stimulator cell and stimulationmethod used, the efﬁcien-
cy by which the MuV-speciﬁc CD4+ or CD8+ T cells are activated and
detected in the IFNγ ELISPOT assay may be affected. With live virus
stimulation, newly synthesized viral antigens are expected to efﬁcientlyenter theMHCclass I loadingpathway in virus-infected APC, thereby ca-
pable to activate antigen-speciﬁc CD8+ T cells. On the other hand,
inactivated virus stimulation would rather result in presentation of an-
tigens via endocytosis into the MHC class II route of APC, stimulating
antigen-speciﬁc CD4+ T cells. However, cross-presentation of exoge-
nous viral antigens in MHC class I molecules by APC also occurs
(Heath and Carbone, 2001). The CD4+ and CD8+ T cell contribution to
the mumps-speciﬁc IFNγ response after live compared to inactive
MuV stimulation remains to be elucidated, yet both live and inactive
MuV stimulation resulted in detectable mumps-speciﬁc IFNγ responses
in CD56-depleted PBMC measured by ELISPOT. We preferred stimula-
tion with live MuV, since antigen uptake and processing would rather
mimic the in vivo situation and higher frequencies of MuV-speciﬁc T
cells were detected (Figs. 2D and 4B).
So far, studies investigatingMuV-speciﬁc cellular immunity are lim-
ited. MuV-speciﬁc proliferative responses and IFNγ secretion have been
detected in PBMC from adults long-term (10–21 years) after MMR vac-
cination as well as from adults that had natural infection during child-
hood (Jokinen et al., 2007; Hanna-Wakim et al., 2008; Vandermeulen
Fig. 4. Contribution of CD56+NK cells inMuV-speciﬁc IFNγ production inhealthy donors andmumpspatients. Cryopreserved PBMCof healthy adults (n=4) andmumpspatients (n=4)
were thawed and depleted for CD56+ cells (CD56− PBMC) or not (PBMC) and stimulatedwith live or inactiveMuV ormock control as indicated. The presence of IFNγ-producing cells was
analyzed by ELISPOT after 24 h. (A) Results shown are themeanMuV-speciﬁc IFNγ-response after CD56-depletion relative to the IFNγ-responsemeasured in PBMC (set at 100)± SD of 4
healthy donors and 4mumpspatients. * p b 0.05. (B) Representative IFNγ ELISPOTwells frommumpspatient-derived PBMC, CD56− PBMC and CD56+ cells stimulatedwith live or inactive
MuV or mock control as indicated. The numbers in the lower left corners indicate counted spots.
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population could indicate insufﬁcient cellular immunity to MuV. Im-
proved assays are necessary to assess the magnitude and quality of
MuV-speciﬁc T cell responses in vaccinated individuals and mumps pa-
tients.We developed an IFNγ ELISPOT assay to investigateMuV-speciﬁc
T cell responses that requires limited clinical material. In addition to
previous studies using MuV lysate stimulation (Ott et al., 2004; Borte
et al., 2009), we used live MuV stimulation in the ELISPOT assay. A
ﬂowcytometric-based assay to investigateMuV-speciﬁc T cell responses
is feasible using live MuV (Fig. 3) or MuV lysate (Hanna-Wakim et al.,
2008; Okhrimenko et al., 2014) stimulation and can discriminate be-
tween CD4+ and CD8+ T cells. These assays do require state-of-the art
equipment and more clinical material, therefore may not be suitable
for all laboratories or clinical studies. Furthermore, peptide stimulations
instead of virus stimulations would be a useful method to investigate T
cell responses in ELISPOT or ﬂowcytometry assays. Unfortunately, no
MuV T cell epitopes have been described in literature, prohibiting this
strategy at this moment.
In the last decades, several mumps outbreaks have occurred in vac-
cinated populations, yet the underlying immunological mechanisms of
this vaccine failure are not clear. We developed an IFNγ ELISPOT for
the analysis of human T cell response against MuV. We recommendCD56-depletion of PBMC before stimulation with live MuV, since we
have shown that CD56+ NK cells can also produce IFNγ after MuV-
speciﬁc stimulation. This assay can be used to evaluate the mumps-
speciﬁc T cell response in MuV vaccinated or infected persons and to
investigate whether sub-optimal T cell immunity plays a role in the
susceptibility to mumps.
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